American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:
“To celebrate the launch of our Self-Evaluation Program (ASCO-SEP): 2025 Digital Edition and Question Bank, we’re highlighting some of its key clinical cases as we count down to board exams in November. Get ready to test your knowledge with real-world scenarios and the latest oncology guidance.
ASCO-SEP is a 12-month digital subscription designed for board preparation and clinical excellence. The subscription boasts 22 evidence-based chapters that include case studies written, edited, and peer-reviewed by experts. This essential oncology toolkit also includes access to the ever-growing Question Bank, which now has 1,400+ questions and rationales, so you can evaluate your reasoning and apply what you’ve learned.
Get board-ready with ASCO-SEP!
Test Prep With ASCO-SEP: Pop Quiz!
Q1: Stage IIIB Left Breast Cancer
A 43-year-old woman was diagnosed with stage IIIB left breast cancer 8 months ago. She underwent neoadjuvant weekly paclitaxel and dose-dense doxorubicin and cyclophosphamide (AC-T). She completed a lumpectomy and a sentinel lymph node biopsy, followed by an axillary lymph node dissection, as the sentinel lymph node was positive. After completing AC-T chemotherapy, her stage was ypT1c (1.4 cm), ypN2 (four positive lymph nodes removed). The tumor was grade 3, estrogen receptor positive (100%), progesterone receptor positive (80%), and HER2 negative (0 on immunohistochemistry [IHC]). Both her mother and older sister have had breast cancer at ages 45 and 49 years, respectively. Genetic testing revealed a pathogenic mutation in the BRCA2 gene. She just completed radiation therapy.
In addition to endocrine therapy, which of the following should you recommend now?
- Capecitabine
- Olaparib
- Capecitabine, followed by olaparib
- No adjuvant therapy
Check back tomorrow to see if you were right!”
More posts featuring ASCO.